57 reports

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Incyte Corporation

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Blood Disease
  • Digestive System Disorder
  • Immunotherapy
  • Stroke
  • TaiwanJ Pharmaceuticals Co., Ltd.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying anti-rheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Incyte Corporation

In December 2002, Amgen initiated another Phase II double-blind, placebo controlled, randomized, parallel-group clinical trial with multiple dose treatment of anti-il ## human monoclonal antibody (AMG ##) in patients with active rheumatoid arthritis who have previously failed one or more d

  • Blood Disease
  • Digestive System Disorder
  • United States
  • Company
  • Product Initiative

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Incyte Corporation

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • World
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

Day ## must start in AM.

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • Therapy
  • Rigel Pharmaceuticals, Inc.
  • ATOPIC DERMATITIS.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying anti-rheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Immunotherapy
  • Stroke
  • Incyte Corporation

Diclofenac sodium (Voltaren) is a benzene-acetic acid derivative.

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • CSL Limited

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • Type 2 Diabetes
  • United States

The study lasted for ## year.

  • Blood Disease
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • GASTRITIS - PIPELINE BY BCWORLD PHARM CO LTD, H1 2018

IBS is one of the most common gastrointestinal disorders.

  • Blood Disease
  • Digestive System Disorder
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Digestive System Disorder
  • Stroke
  • Therapy
  • United States
  • Product Initiative

The study lasted for ## year.

  • Blood Disease
  • Digestive System Disorder
  • United States
  • World
  • Product Initiative

The study will be conducted with patients with active arthritis who are referred to the special department for treatment with antirheumatic drugs that treat diseases where first-line treatment is methotrexate.

  • Blood Disease
  • Digestive System Disorder
  • China
  • World
  • Product Initiative

Day ## must start in AM.

  • Autoimmune Disease
  • Blood Disease
  • Digestive System Disorder
  • United States
  • Product Initiative

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Blood Disease
  • Digestive System Disorder
  • Medical Biotechnology
  • Stroke
  • Pfizer Inc.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Product Initiative
  • SUBJECTS WITH CROHN'S DISEASE. THE TRIAL WAS REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.

ABBVIE REGISTERED THE FOLLOWING PHASE III TRIALS WITH THE TITLES RANDOMIZED, DOUBLE-BLIND, SELECT- PSA ## STUDY COMPARING ABT-## TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE A HISTORY OF INADEQUATE RESPONSE TO AT LEAST ONE NON-BIOLOGIC DISEASE M

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Company

If approved, Xeljanz in combination with methotrexate (MTX) will be indicated for the treatment of moderate to severe active RA in adult patients who have responded inadequately to, or who are intolerant to one or more diseasemodifying antirheumatic drugs.

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • Therapy
  • Pfizer Inc.

SUBJECTS ARE MAINTAINED ON EACH DOSE FOR AT LEAST TWO TO THREE CONSECUTIVE WEEKS (ONE WEEK STABILIZATION + ONE AND A HALF WEEKS TESTING).

  • Blood Disease
  • Digestive System Disorder
  • Hospital
  • Stroke
  • MediciNova, Inc.

PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RA WHO HAD AN INADEQUATE RESPONSE TO AT LEAST ONE DISEASE- MODIFYING ANTIRHEUMATIC DRUG (DMARD) RECEIVED TASOCITINIB ## MG OR ## MG MONOTHERAPY OR PLACEBO TWICE A DAY.

  • Blood Disease
  • Digestive System Disorder
  • Medical Biotechnology
  • Stroke
  • Pfizer Inc.

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Blood Disease
  • Digestive System Disorder
  • Monoclonal Antibody
  • Stroke
  • United States

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Product Initiative

One external remote patient monitoring device consists of one external module or transmitter.

  • Blood Disease
  • Cardiovascular Disease
  • Stroke
  • United States
  • Pfizer Inc.

ADC is one such approach.

  • Blood Disease
  • Digestive System Disorder
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novo Nordisk Group

The study lasted for ## year.

  • Blood Disease
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative

It also provides gastrointestinal agents, anti-rheumatic, narcotics, vitamin B## supplements and vitamin C supplements, anti-spasmodic, and autonomic nervous systems, among others.

  • Blood Disease
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Molecular Diagnostics
  • Therapy

In December 2002, Amgen initiated another Phase II double-blind, placebo controlled, randomized, parallel-group clinical trial with multiple dose treatment of anti-il ## human monoclonal antibody (AMG ##) in patients with active rheumatoid arthritis who have previously failed one or more d

  • Blood Disease
  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • CX-611 - DRUG PROFILE

FRANZ KOHLER CHEMIE GMBH CYTACOAT AB ENDACEA INC ENLIVEX THERAPEUTICS LTD ENZYCHEM LIFESCIENCES CORP EUNOIA BIOTECH LLC EXOXEMIS INC EXPRESSION DRUG DESIGNS LLC GPN VACCINES PVT LTD HIBERNAID INC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Blood Disease
  • Digestive System Disorder
  • Stroke
  • Therapy
  • Bristol-Myers Squibb Company